ENTITY
Jinxin Fertility

Jinxin Fertility (1951 HK)

126
Analysis
Health Care • China
Jinxin Fertility Group is a leading international provider of assisted reproductive services (ARS) and assisted reproductive technology (ART). Its core offerings include In Vitro Fertilization (IVF), Intrauterine Insemination (IUI), egg retrieval, embryo transfer, and genetic screening, alongside a range of women's health services. The company is headquartered in Chengdu, China, and was founded in 1951.
more
•29 Mar 2021 16:17

Jinxin Fertility: Long Term IVF Story Intact Despite Potential Post Results De-Rating

We believe that the recent share weakness was mainly due to the risk-off sentiment in the market. Demands for IVF services are secular and the moat...

Logo
356 Views
Share
•23 Feb 2021 09:40

Jinxin Fertility (1951.HK) - The New Policy, the Logic and the Risk Factors

This article analyzed Jinxin Fertility in terms of the industry characteristics (entry barrier), business model (expansion mode, talent, merger and...

Logo
488 Views
Share
•22 Feb 2021 17:17

Asia Short Interest: Lenovo, AIA, Nongfu, Wuxi Bio, Toshiba, Freee, Canon, Samsung, Celltrion, TSMC

The Insight looks at large short interest movements across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
385 Views
Share
•16 Feb 2021 18:11

Asia Short Interest: WuXi Bio, PSBC, Jinxin Fertility, BYD, Ryohin, Freee, Itochu, Pearl Abyss

The Insight looks at large short interest movements across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
377 Views
Share
•07 Feb 2021 15:13

Suzhou Basecare Medical IPO: Trading Debut

Basecare priced its IPO at HK$27.36 and closed 14% up at HK$31.20 in the grey market. Our DCF sensitivity analysis shows that the IPO price is...

Logo
470 Views
Share
x